AR882, a potent and selective URAT1 inhibitor with a favorable pharmacological, pharmacokinetic and toxicity profile.

ACR 2019

AR882, a potent and selective uric acid lowering agent acting through inhibition of uric acid reuptake, shows excellent pharmacokinetics and pharmacodynamics in a phase 1 clinical trial.

ACR 2019

AR882, a potent and selective uricosuric agent, significantly reduced serum urate levels following multiple ascending once-daily doses in healthy subject volunteers.

ACR 2020

AR882, a potent and selective uricosuric agent, significantly reduced serum urate in patients with gout in a phase 2a study.

ACR 2020

Pharmacokinetics and serum urate lowering effects of AR882, a novel, potent and selective uricosuric agent, in patients with gout.

EULAR 2021

Combination treatment of AR882, a new URAT1 inhibitor, and xanthine oxidase inhibitors allopurinol or febuxostat: effect on uric acid, hypoxanthine and xanthine in plasma or serum and urine.

EULAR 2021

AR882, a potent and selective uricosuric agent, showed effectiveness in patients with various degrees of renal impairment.

ACR 2021

AR882, a novel uricosuric agent, exhibited favorable pharmacokinetic profile and balanced excretion and metabolic pathways in a human AME study.

ACR 2021

(Late-breaker) AR882, an Efficacious and Selective URAT1 Inhibitor for Patients with Chronic Gouty Arthritis and Subcutaneous Tophi: Results from a Global, Prospective, Proof-of-Concept Trial Using Dual Energy Computed Tomography

ACR Convergence 2023

Efficacy and Safety of AR882, a Selective Uric Acid Transporter 1 (URAT1) Inhibitor, in Gout Patients with Various Baseline Characteristics Following 12-Week Treatment in Patients

ACR Convergence 2023

Pharmacokinetics and Pharmacodynamics of AR882 Following 12-Week Treatment in Patients with Gout

ACR Convergence 2023

AR882, a Potent Uricosuric Agent, Shows Favorable Uric Acid Excretion Profile Following Multiple Doses